California Public Employees Retirement System Decreases Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

California Public Employees Retirement System trimmed its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 2.2% during the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 363,496 shares of the biopharmaceutical company's stock after selling 8,142 shares during the period. California Public Employees Retirement System owned about 0.33% of Regeneron Pharmaceuticals worth $258,929,000 as of its most recent filing with the SEC.

Several other large investors have also recently made changes to their positions in REGN. FSA Wealth Management LLC acquired a new stake in Regeneron Pharmaceuticals in the 3rd quarter valued at approximately $26,000. Rakuten Securities Inc. boosted its position in shares of Regeneron Pharmaceuticals by 62.5% during the fourth quarter. Rakuten Securities Inc. now owns 39 shares of the biopharmaceutical company's stock worth $28,000 after buying an additional 15 shares during the period. OFI Invest Asset Management acquired a new stake in shares of Regeneron Pharmaceuticals in the fourth quarter valued at $28,000. Larson Financial Group LLC raised its holdings in shares of Regeneron Pharmaceuticals by 127.3% in the 3rd quarter. Larson Financial Group LLC now owns 50 shares of the biopharmaceutical company's stock valued at $53,000 after buying an additional 28 shares during the period. Finally, Avalon Trust Co acquired a new position in Regeneron Pharmaceuticals during the 4th quarter worth about $36,000. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on REGN. Bernstein Bank cut their price target on shares of Regeneron Pharmaceuticals from $1,070.00 to $1,000.00 in a research note on Tuesday, February 4th. Canaccord Genuity Group downgraded shares of Regeneron Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, December 17th. Leerink Partners upgraded shares of Regeneron Pharmaceuticals from a "market perform" rating to an "outperform" rating and boosted their price target for the stock from $762.00 to $834.00 in a research note on Wednesday, February 5th. Canaccord Genuity Group assumed coverage on Regeneron Pharmaceuticals in a research note on Tuesday, December 17th. They set a "hold" rating and a $165.00 target price for the company. Finally, Truist Financial reduced their price target on Regeneron Pharmaceuticals from $1,126.00 to $1,004.00 and set a "buy" rating on the stock in a research report on Wednesday, January 8th. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating, seventeen have assigned a buy rating and two have issued a strong buy rating to the company. According to MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $966.88.

Regeneron Pharmaceuticals Stock Performance

Shares of NASDAQ REGN traded down $4.81 during midday trading on Thursday, reaching $620.79. 324,070 shares of the company were exchanged, compared to its average volume of 678,349. The stock has a market cap of $67.87 billion, a P/E ratio of 16.22, a PEG ratio of 2.34 and a beta of 0.27. Regeneron Pharmaceuticals, Inc. has a 1 year low of $605.56 and a 1 year high of $1,211.20. The stock has a fifty day simple moving average of $680.43 and a 200 day simple moving average of $786.93. The company has a current ratio of 4.73, a quick ratio of 3.95 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last announced its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share for the quarter, beating the consensus estimate of $11.21 by $0.86. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The company had revenue of $3.79 billion for the quarter, compared to the consensus estimate of $3.76 billion. During the same period last year, the business posted $11.86 EPS. The company's revenue was up 10.3% on a year-over-year basis. On average, research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Thursday, March 20th. Stockholders of record on Thursday, February 20th were paid a dividend of $0.88 per share. The ex-dividend date of this dividend was Thursday, February 20th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.57%. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is 2.30%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.